FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use
1. FDA extended AGIO's PDUFA goal date to December 7, 2025. 2. Agios submitted a Risk Evaluation and Mitigation Strategy (REMS) for Pyrukynd. 3. The extension was not due to new safety or efficacy data. 4. Saudi Arabia approved Pyrukynd for thalassemia patients last month. 5. AGIO stock is currently down 15.83% at $34.18.